Recently in Research Category

panama-city-skyline.jpgThe following is a recent report released by the CDC about links between HIV and poverty levels in urban areas.

'New Study in Low-Income Heterosexuals in America's Inner Cities Reveals High HIV Rates

VIENNA - The Centers for Disease Control and Prevention today released a first-of-its-kind analysis showing that 2.1 percent of heterosexuals living in high-poverty urban areas in the United States are infected with HIV. This analysis suggests that many low-income cities across the United States now have generalized HIV epidemics as defined by the United Nations Joint Program on HIV/AIDS (UNAIDS).

UNAIDS defines a generalized epidemic as one that is firmly established in the general population, with an overall HIV prevalence in the general population of more than 1 percent. While subpopulations with higher risk (such as men who have sex with men and injection drug users) may still contribute disproportionately to the spread of HIV in these areas, heterosexual transmission is also sufficient to sustain an epidemic independent of those groups.

The analysis also shows that poverty is the single most important demographic factor associated with HIV infection among inner-city heterosexuals. Contrary to severe racial disparities that characterize the overall U.S. epidemic, researchers found no differences in HIV prevalence by race/ethnicity in this population. The analysis will be presented at the XVIII International AIDS Conference in Vienna, Austria.

"This study reveals a powerful link between poverty and HIV risk, and a widespread HIV epidemic in America's inner cities," said Kevin Fenton, M.D., Ph.D., director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. "In this country, HIV clearly strikes the economically disadvantaged in a devastating way."

The analysis, led by Paul Denning, M.D., a medical epidemiologist in CDC's Division of HIV/AIDS Prevention, included more than 9,000 heterosexual adults (aged 18-50) in high-poverty areas of 23 cities who participated in the 2006-2007 heterosexual cycle of the CDC's National HIV Behavioral Surveillance System. This system monitors HIV risk behaviors, HIV testing patterns, and use of HIV prevention services among U.S. populations at risk.

High-poverty areas were defined according to the U.S. Census Bureau, and included areas in which at least 20 percent of residents have household incomes below the poverty line.

Nationally, the United States is considered to have a concentrated HIV epidemic, meaning that it is confined mainly to individuals who engage in high-risk behaviors, which in the United States are primarily gay and bisexual men and injection drug users.

For this analysis, researchers followed UNAIDS criteria for determining a generalized epidemic, and excluded groups at highest risk for becoming HIV infected. Those groups not included in this analysis were gay and bisexual men - who continue to represent the majority of new HIV infections in the United States - injection drug users, and sex workers and their clients.

"These findings have significant implications for how we think about HIV prevention. We can't look at HIV in isolation from the environment in which people live," said Jonathan Mermin, M.D., director of CDC's Division of HIV/AIDS Prevention. "This analysis points to an urgent need to prioritize HIV prevention efforts in disadvantaged communities. We are pleased that President Obama's new National HIV/AIDS Strategy reflects this type of approach, in terms of targeting HIV prevention resources to those in greatest need."

Prevalence was especially high in those with the lowest socioeconomic status. Within the low income urban areas included in the study, individuals living below the poverty line were at greater risk for HIV than those living above it (2.4 percent prevalence vs. 1.2 percent), though prevalence for both groups was far higher than the national average (0.45 percent). There were no significant differences in HIV prevalence by race or ethnicity in these low income urban areas: prevalence was 2.1 percent among blacks, 2.1 percent among Hispanics, and 1.7 percent among whites. By contrast, the U.S. epidemic overall is characterized by severe racial/ethnic disparities: the HIV prevalence rate for blacks is almost 8 times that of whites, and the HIV prevalence rate among Hispanics is nearly 3 times that of whites.

The absence of race-based differences in this analysis is likely due to existing high prevalence of HIV in poor urban areas, which - regardless of race or ethnicity - places individuals living in these areas at greater risk for exposure to HIV with each sexual encounter.

Authors note that other factors associated with poverty also likely contribute to high HIV prevalence in these settings. Some of these factors include limited health care access, which can reduce utilization of HIV testing and prevention services; substance abuse, which can increase sexual risk behavior; and high rates of incarceration, which can disrupt the stability of relationships.

This analysis provides greater insight into factors that may be driving heterosexual HIV transmission in the United States, which accounts for 31 percent of new infections each year. This study did not examine HIV prevalence among groups at higher risk for HIV in these areas, including MSM and IDU. Nationally, MSM account for 53 percent of new infections, IDU account for 12 percent, and those exposed through both MSM and IDU account for 4 percent.

For more information on HIV in the United States, please visit http://www.cdc.gov/hiv, or http://www.cdc.gov/nchhstp/newsroom.'

720px-US-NIH-NIAID-Logo.svg.pngStatement of Anthony S. Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases National Institutes of Health on Results from the CAPRISA 004 Microbicide Study

"Today we congratulate the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

For years, antiretroviral medicines have been effectively used to treat HIV infection. Through the successful conduct of the CAPRISA 004 study, we now have proof that an antiretroviral drug, in this case tenofovir, can be formulated into a vaginal gel that can protect women against HIV infection. Given that women make up the majority of new HIV infections throughout the world this finding is an important step toward empowering an at-risk population with a safe and effective HIV prevention tool.

For more information, go to http://www.niaid.nih.gov/news/newsreleases/2010/Pages/CAPRISA.aspx."

From The DC Center:

Below are links to various articles from news outlets around the country today about the study's results.

CNN

Science Daily

NPR

The New York Times

CAVE Monthly Meeting September 8th

| No Comments | No TrackBacks

cavemtg1.pngJoin us for the next Capital Area Vaccine Effort Meeting on September 8th at 7:00 PM at the DC Center for the LGBT Community, 1318 U Street NW. The DC is located a short distance from the U Street Cardozo Metro Station.

We will be planning our fall HIV prevention research fall lunch series and planning for our Fall Retreat. Please note there will be no monthly meeting in August.

Capital Area Vaccine Effort is a volunteer panel of individuals from the general public and from the diverse communities affected by AIDS. CAVE serves as the community advisory board for the Vaccine Research Center and the Rockville Vaccine Assessment Clinic. CAVE is organized to assist and advise AIDS vaccine trials in the metropolitan DC area.

AIDsRibbon.jpgThis week, the White House, through the Office of National AIDS Policy, has released a national HIV/AIDS Strategy and Implementation plan. The Vision for the Strategy states;

"The United States will become a place where new HIV infections are rare and when they do occur, every person, regardless of age, gender, race/ethnicity, sexual orientation, gender identity, or socio-economic circumstances, will have unfettered access to high quality, life-extending care, free from stigma and discrimination."

The report then outlines three primary goals. "...1) reducing the number of people who become infected with HIV, 2) increasing access to care and optimizing health outcomes for people living with HIV, and 3) reducing HIV-related health disparities." The report is also accompanied by an Implementation Plan that outlines the "measurable goals, timelines, and accountability mechanisms" that were promised by the President.

You can find the offical Stratgey and its Implementation Plan here.

You can watch a video of the the announcement and launch here at AIDS.gov.

Following is a list of articles about the report, labeled by news source:

ABC News

USA Today

New York Times

_icons_cdc_logo.jpgA new report by the CDC has some very optimistic findings about the testing and diagnosis rates of HIV in the District. According to the report:

"During 2004--2008..., the overall number and rate of newly diagnosed AIDS cases decreased 35%, from 164 cases per 100,000 to 107 cases per 100,000 (EAPC = -9.2; p<0.001). The decrease was 58% among Hispanics/Latinos (EAPC = -17.8; p<0.001), 32% among blacks/African Americans (EAPC = -7.1; p=0.002), and 23% among whites (EAPC = -6.9; p<0.001).

The overall proportion of persons newly diagnosed with HIV who had a CD4 count within 3 months of diagnosis increased, from 62% in 2004 to 64% in 2008 (p=0.006). The only significant increase in this proportion by racial/ethnic group was observed among blacks/African Americans, from 60% in 2004 to 63% in 2008 (p=0.009).

During 2004--2008, the number of publicly funded HIV tests in DC increased by 335% (from 16,748 tests in 2004 to 72,864 in 2008) among community-based and clinical providers, including a 415% increase among blacks/African Americans (from 10,924 in 2004 to 56,278 in 2008) (Figure). The number of persons testing positive increased by 353%, from 246 in 2004 to 1,115 in 2008. The proportion of persons testing positive in 2004 and 2005 was 1.5% and 1.8%, respectively. This proportion peaked in 2006 at 2.5%, and then decreased to 1.4% and 1.7% in 2007 and 2008, respectively."

Read the rest of the report here.

720px-US-NIH-NIAID-Logo.svg.pngDuring the next several weeks, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will post a series of blog entries on www.AIDS.gov related to planning for the future of NIAID’s HIV/AIDS clinical trial networks. The awards supporting the six current HIV/AIDS networks are set to expire in 2013 and 2014.

Building upon the success of the current networks, NIAID aims to broaden the scope of the networks to include research for other infectious diseases of significance to people with or at risk for HIV infection, namely tuberculosis, malaria and hepatitis. Further, the institute is looking for ways to increase collaboration across the networks; create transparent mechanisms for network leadership to solicit and support ideas from the research community; develop a means for external researchers to tap into the clinical trial infrastructure and capacity that the network system provides; and ensure that each network is capable of designing and implementing a cross-network agenda to address research questions related to specific populations.

Through the blog series, NIAID is seeking input from the broader research and HIV/AIDS communities on specific aspects of the network restructuring. Specifically, the blog posts will address:

- NIAID’s clinical research priority areas: prevention, therapeutics and vaccines;
- The structure of the new networks; and
- The relationship between network leadership groups and clinical research sites.

Thoughtful comments and opinions on each of the blog posts are strongly encouraged as they will help NIAID to determine the future direction of its clinical trial networks.

Please check out the blog series at the blog’s Research page.

Media inquiries can be directed to the NIAID Office of Communications at 301-402-1663, niaidnews@niaid.nih.gov.

----------

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

wet.jpgThe following is a link to an article from the Times Live blog about lubricants used when having anal sex.

Risk of sexually transmitted disease three times higher when lubricant used with anal sex

CAVE Meeting June 9th

| No Comments | No TrackBacks
cavemtg1.pngJoin us for the next Capital Area Vaccine Effort Meeting on June 9th at 7:00 PM at the offices of Us Helping Us, 3636 Georgia Avenue, NW. Us Helping Us is located a short distance from the Georgia Ave / Petworth Metro Station.

Capital Area Vaccine Effort is a volunteer panel of individuals from the general public and from the diverse communities affected by AIDS. CAVE serves as the community advisory board for the Vaccine Research Center and the Rockville Vaccine Assessment Clinic. CAVE is organized to assist and advise AIDS vaccine trials in the metropolitan DC area.

At this meeting Matt Rancourt will report back from the HIV Vaccine Trials Network Community Advisory Board Member Retreat.

See Pictures of our recent events

To see pictures of our HIV Vaccine Awareness Day Lunch: CLICK HERE
To see pictures of our HIV Vaccine Awareness Outreach Night: CLICK HERE




Vaccine Basics: HIV Vaccine Awareness Day Lunch

| No Comments | No TrackBacks

vaccinebasics1.gif

The DC Center and the Capital Area Vaccine Effort invite you to a presentation on the basics of HIV Vaccine Research.

This free lunch presentation takes place on HIV Vaccine Awareness Day, May 18th at 12:30 PM at the DC Center for the LGBT Community, 1810 14th Street NW.

Please join us a presentation by the Vaccine Research Center on HIV Vaccine Research and learn about a new HIV Vaccine study that is recruiting gay and bisexual men and transgender women.





CAVE Meeting March 10th

| No Comments | No TrackBacks

cave1.gifThe next CAVE meeting will take place March 10th at 7:00 PM at the DC Center, 1810 14th St, NW. Our meetings normally take place the second Wednesday of each month.

CAVE is the community advisory board for the Vaccine Research Center and the US Military HIV Research Program. Capital Area Vaccine Effort is a volunteer panel of individuals from the general public and from the diverse communities affected by AIDS. CAVE is organized to assist and advise AIDS vaccine trials in the metropolitan DC area. For more information visit www.aidsvaccine.org.

 

Hope Takes Action: New Facebook Group

| No Comments | No TrackBacks

hopetakesaction1.gifAre you a man between 18-45 years old and HIV negative? Volunteer for a local HIV vaccine study and turn hope into action.

Every 10 minutes, someone in the United States is infected with HIV. A preventive vaccine against HIV offers the best long-term hope to end this worldwide epidemic. Finding a safe and effective HIV vaccine that will protect people is a huge task. We cannot do it without your help.

Learn more and get updates on the study. Join the Hope Takes Action DC Facebook Group.

click here to join the Hope Takes Action DC Facebook Group.

CAVE Meeting and Protocol Review January 13th

| No Comments | No TrackBacks
The next CAVE meeting will take place January 13th at 6:30 PM at the DC Center, 1810 14th St, NW. Our meetings normally take place the second Wednesday of each month.

One of the roles of CAVE is to review protocols for new HIV vaccine studies and to provide input to the researchers from a community perspective.  We will be reviewing a protocol for the Military HIV Working Group in January.  If you've never done anything like this, don't worry.  The meeting will include an overview of how to review protocols.

CAVE is the community advisory board for the Vaccine Research Center and the US Military HIV Research Program. Capital Area Vaccine Effort is a volunteer panel of individuals from the general public and from the diverse communities affected by AIDS. CAVE is organized to assist and advise AIDS vaccine trials in the metropolitan DC area.  For more information visit www.aidsvaccine.org.

 
Capital Area Vaccine Effort
DC Community AIDS Network!
PreventionWorks!
DC Center HIV Working Group
find us on facebook!find us on youtube!find us on twitter!

fight hiv in dc rss feed!find us on technorati!find us on flickr!

To Sign up for e-mail updates: click here!


Archives

About this Archive

This page is an archive of recent entries in the Research category.

Prevention is the previous category.

Support is the next category.

Find recent content on the main index or look in the archives to find all content.